Latest Hycult Biotech news

Expanding Biocult Services Biocult Expands Services with new Team and Technology UDEN, Netherlands, March 30, 2026 Biocult, part of Hycult Biotechnology B.V., has expanded its organization with new scientific expertise, additional technological capacity, and a strengthened development team. With this...

Vacature Strategic Market & Product Development Manager (28-40 uur per week) Hycult Biotech is gespecialiseerd in de ontwikkeling en productie van immunologische assays, antistoffen en eiwitten binnen het innate immunology veld. Onze producten worden ontwikkeld in samenwerking met toonaangevende wetenschappers...

Adjusted Opening Hours during spring Our operations will be closed on several Dutch public holidays this spring. We kindly encourage you to place your orders in advance to ensure your needs are met before the holiday closures. We will be...

Complement research in drug development Bridging complement biology from discovery to therapy The development of complement-targeting therapeutics requires a clear and reliable path from discovery to preclinical decision-making. A key challenge is translating results from animal studies into data that...

Basically, the Terminal Complement Complex (TCC) and Membrane Attack Complex (MAC) resemble the same protein complex. The complex can exist as membrane bound variant as well as a soluble variant, respectively in general referred to as MAC and soluble TCC...

As of October 1st, 2025, we’re pleased to announce a change in our management structure at Hycult Biotech. Our Managing Director, Ronald de Niet, is stepping back from daily operations to focus on strategy and long-term development as CEO. Marja...

We are happy to introduce our new ELISA kit developed to determine in vitro quantitative C3bBbP levels in serum and plasma samples. The C3 convertase, C3bBbP arises during Alternative Pathway (AP) activation and is an essential factor for proper functioning of...

New Antibody for Detection of the Membrane Attack Complex Figure 1: IHC of Immunohistochemistry (IHC) of C3 glomerulopathy in a kidney biopsy (FFPE tissue) using antibody (HM2443) anti-C5b-9 staining C5b-9 in tissue. The image was kindly provided by Prof. Lubka...

Neurodegenerative diseases pose a significant challenge for individuals and society, and with treatments not always available, there is a critical need for new drugs. Although the precise pathophysiology of these diseases is often poorly understood, studies have shown that complement...

We are happy to introduce to you our new ELISA kits developed to detect human Factor H-related proteins (FHR-2, FHR-3, FHR-4 and FHR-5). The kits were co-developed within the SciFiMed project, a European multi-disciplinary consortium that includes Hycult Biotech and Sanquin...

Bridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following...

We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to...